Ikena Oncology Analyst Ratings
Ikena Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 164.42% | Wedbush | → $11 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/07/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/24/2023 | 332.69% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/16/2023 | 212.5% | Credit Suisse | → $13 | Reiterates | Outperform → Outperform |
| 05/04/2023 | 332.69% | HC Wainwright & Co. | → $18 | Assumes | → Buy |
| 03/17/2023 | 428.85% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 03/15/2023 | 212.5% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 11/29/2022 | 284.62% | Credit Suisse | $18 → $16 | Maintains | Outperform |
| 11/29/2022 | 428.85% | HC Wainwright & Co. | $26 → $22 | Maintains | Buy |
| 11/08/2022 | 332.69% | Credit Suisse | $20 → $18 | Maintains | Outperform |
| 05/13/2022 | 380.77% | Credit Suisse | $24 → $20 | Maintains | Outperform |
| 04/13/2022 | 525% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 12/23/2021 | 500.96% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 08/13/2021 | 549.04% | Credit Suisse | $30 → $27 | Maintains | Outperform |
| 04/20/2021 | — | Jefferies | Initiates Coverage On | → Buy | |
| 04/20/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/20/2021 | 621.15% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/22/2023 | 164.42% | 韦德布什 | →$11 | 开始承保 | →跑赢大盘 |
| 2023年08月10日 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 08/07/2023 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 2023年05月24日 | 332.69% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 2023年05月16日 | 212.5% | 瑞士信贷 | →$13 | 重申 | 跑赢→跑赢大盘 |
| 05/04/2023 | 332.69% | HC Wainwright公司 | →$18 | 假设 | →购买 |
| 03/17/2023 | 428.85% | HC Wainwright公司 | →$22 | 重申 | →购买 |
| 03/15/2023 | 212.5% | 瑞士信贷 | $16→$13 | 维护 | 跑赢大盘 |
| 2022年11月29日 | 284.62% | 瑞士信贷 | $18→$16 | 维护 | 跑赢大盘 |
| 2022年11月29日 | 428.85% | HC Wainwright公司 | $26→$22 | 维护 | 买 |
| 11/08/2022 | 332.69% | 瑞士信贷 | $20→$18 | 维护 | 跑赢大盘 |
| 2022年05月13日 | 380.77% | 瑞士信贷 | $24→$20 | 维护 | 跑赢大盘 |
| 04/13/2022 | 525% | HC Wainwright公司 | $25→$26 | 维护 | 买 |
| 2021年12月23日 | 500.96% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
| 2021/08/13 | 549.04% | 瑞士信贷 | $30→$27 | 维护 | 跑赢大盘 |
| 04/20/2021 | - | 杰富瑞 | 开始承保 | →购买 | |
| 04/20/2021 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 04/20/2021 | 621.15% | 瑞士信贷 | →$30 | 开始承保 | →跑赢大盘 |
What is the target price for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的目标价格是多少？
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by Wedbush on September 22, 2023. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 164.42% upside). 11 analyst firms have reported ratings in the last year.
韦德布什于2023年9月22日报道了Ikena Oncology(纳斯达克：IKNA)的最新目标价。这家分析公司将目标价定为11美元，预计宜家航空将在12个月内上涨至11美元(涨幅可能为164.42%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的最新分析师评级是多少？
The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by Wedbush, and Ikena Oncology initiated their outperform rating.
对Ikena Oncology(纳斯达克代码：IKNA)的最新分析师评级是由韦德布什提供的，Ikena Oncology发起了他们的表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Ikena Oncology(IKNA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Ikena Oncology的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Ikena Oncology的上一次评级是在2023年9月22日提交的，所以你应该预计下一次评级将在2024年9月22日左右提供。
Is the Analyst Rating Ikena Oncology (IKNA) correct?
分析师对Ikena Oncology(IKNA)的评级正确吗？
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a initiated with a price target of $0.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $4.16, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Ikena Oncology(IKNA)评级是以0.00美元至11.00美元的目标价启动的。Ikena Oncology(IKNA)目前的交易价格为4.16美元，在分析师的预测范围内。